First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
First Tracks Biotherapeutics (Nasdaq: TRAX) will host an investor call and webcast on Oct. 12, 2026, at 8:30am ET to review top-line data from Cohort 1 of the Phase 1b trial of ANB033, a CD122 antagonist, in celiac disease. Cohort 1 is a gluten-challenge study assessing prevention of mucosal damage; data will be issued in a morning press release and presented during the webcast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.